Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Olfactory receptor family 52 subfamily U member 1 pseudogene (OR52U1P) is classified as a pseudogene within the human olfactory receptor gene family. Unlike functional olfactory receptor genes, pseudogenes typically possess disruptive mutations and do not encode active protein products or mediate cellular functions. OR52U1P does not participate in signal transduction or odorant recognition and is not considered a therapeutic target, receptor, enzyme, transporter, or biomarker. The designation as a pseudogene indicates loss of coding potential—there is no evidence of physiological or pharmacological activity for OR52U1P. In human genetics, olfactory receptor pseudogenes (including OR52U1P) are common due to the dynamic evolution and relaxed selective pressure associated with odorant receptor gene families. Observations of "pseudo-pseudogenes" (pseudogenes which may encode functional proteins in other organisms) are emerging in some animal models (e.g., Drosophila), but there is no evidence of such readthrough or functional activity for OR52U1P in humans. OR52U1P remains annotated as a pseudogene and not a viable molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Olfactory receptor family 52 subfamily U member 1 pseudogene (OR52U1P).